IPOS - Medical device maker Marizyme files to uplist shares conduct $15M offering

Medical device maker Marizyme (OTCQB:MRZM) is seeking to uplist its shares to Nasdaq and conduct a public offering of around $15M. The maker of grafting treatments for use in coronary bypass surgery said in a filing that it plans to offer 3M shares in the range of $4 to $6. Underwriters will be offered a 45-day option to purchase up to 450K additional shares at the public price.  Univest Securities is serving as lead bookrunner on the deal. Marizyme shares, which currently trade on the OTC market, closed at $1.65 per share on Friday. The company has a market capitalization of approximately $70M. Marizyme’s flagship product is DuraGraft, which is used to help prevent complications from grafting in vascular surgeries. The company is also developing consumer-focused diagnostic devices that can be linked to smart phones.

For further details see:

Medical device maker Marizyme files to uplist shares, conduct $15M offering